116 related articles for article (PubMed ID: 35689385)
1. Tamoxifen use and potential effects on liver parenchyma: A long-term prospective transient elastographic evaluation.
Braal CL; de Knegt RJ; Jager A; Koolen SLW; Mathijssen RHJ; Eechoute K
Hepatol Commun; 2022 Sep; 6(9):2565-2568. PubMed ID: 35689385
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
3. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
4. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
[TBL] [Abstract][Full Text] [Related]
5. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
[TBL] [Abstract][Full Text] [Related]
6. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
[TBL] [Abstract][Full Text] [Related]
7. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
[TBL] [Abstract][Full Text] [Related]
10. The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort.
Cardoso AC; Cravo C; Calçado FL; Rezende G; Campos CFF; Neto JMA; Luz RP; Soares JAS; Moraes-Coelho HS; Leite NC; Perez RM; Villela-Nogueira CA
Eur J Gastroenterol Hepatol; 2020 Feb; 32(2):231-238. PubMed ID: 31464788
[TBL] [Abstract][Full Text] [Related]
11. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations.
de Lédinghen V; Vergniol J; Capdepont M; Chermak F; Hiriart JB; Cassinotto C; Merrouche W; Foucher J; Brigitte le B
J Hepatol; 2014 May; 60(5):1026-31. PubMed ID: 24378529
[TBL] [Abstract][Full Text] [Related]
12. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease.
Shen F; Zheng RD; Shi JP; Mi YQ; Chen GF; Hu X; Liu YG; Wang XY; Pan Q; Chen GY; Chen JN; Xu L; Zhang RN; Xu LM; Fan JG
Liver Int; 2015 Nov; 35(11):2392-400. PubMed ID: 25689614
[TBL] [Abstract][Full Text] [Related]
13. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP).
Cardoso AC; Perez RM; de Figueiredo-Mendes C; Carvalho Leite N; Moraes-Coelho HS; Villela-Nogueira CA
J Viral Hepat; 2018 Nov; 25(11):1244-1250. PubMed ID: 29768686
[TBL] [Abstract][Full Text] [Related]
15. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
Chan WK; Nik Mustapha NR; Mahadeva S
J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
[TBL] [Abstract][Full Text] [Related]
16. How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis?
Trowell J; Alukal J; Zhang T; Liu L; Maheshwari A; Yoo HY; Thuluvath PJ
Dig Dis Sci; 2021 Apr; 66(4):1297-1305. PubMed ID: 32337667
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery.
Tavaglione F; De Vincentis A; Bruni V; Gallo IF; Carotti S; Tuccinardi D; Spagnolo G; Ciociola E; Mancina RM; Jamialahmadi O; D'Alessio R; Bottazzi B; Manfrini S; Picardi A; Perrone G; Pozzilli P; Caricato M; Vespasiani-Gentilucci U; Romeo S
Liver Int; 2022 Feb; 42(2):374-383. PubMed ID: 34890093
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements.
Mikolasevic I; Lukenda Zanko V; Jakopcic I; Domislovic V; Mijic A; Stevanovic T; Delija B; Bokun T; Dinjar Kujundzic P; Ostojic A; Filipec Kanizaj T; Grgurevic I; Krznaric Z; Stimac D; Targher G
J Diabetes Complications; 2020 Mar; 34(3):107512. PubMed ID: 31882273
[TBL] [Abstract][Full Text] [Related]
19. Discordance in steatosis classification between liver biopsy and transient elastography for high controlled attenuation parameter (CAP) values.
Galaski J; Schulz L; Krause J; Lohse AW
Z Gastroenterol; 2018 Jan; 56(1):36-42. PubMed ID: 29316576
[TBL] [Abstract][Full Text] [Related]
20. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.
Shalimar ; Kumar R; Rout G; Kumar R; Yadav R; Das P; Aggarwal S; Gunjan D; Saraya A; Nayak B
Indian J Gastroenterol; 2020 Feb; 39(1):32-41. PubMed ID: 32185692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
